Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141(+) dendritic cells to activate naïve and memory WT1‐specific CD8(+) T cells

OBJECTIVES: Vaccines that prime Wilms' tumor 1 (WT1)‐specific CD8(+) T cells are attractive cancer immunotherapies. However, immunogenicity and clinical response rates may be enhanced by delivering WT1 to CD141(+) dendritic cells (DCs). The C‐type lectin‐like receptor CLEC9A is expressed exclus...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Transl Immunology
Asıl Yazarlar: Pearson, Frances E, Tullett, Kirsteen M, Leal‐Rojas, Ingrid M, Haigh, Oscar L, Masterman, Kelly‐Anne, Walpole, Carina, Bridgeman, John S, McLaren, James E, Ladell, Kristin, Miners, Kelly, Llewellyn‐Lacey, Sian, Price, David A, Tunger, Antje, Schmitz, Marc, Miles, John J, Lahoud, Mireille H, Radford, Kristen J
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2020
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7292901/
https://ncbi.nlm.nih.gov/pubmed/32547743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cti2.1141
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller